CELA2A

Summary

CELA2A (chymotrypsin like elastase 2A, HGNC:24609) is a protein-coding gene on chromosome 1p36.21, encoding Chymotrypsin-like elastase family member 2A (P08217). Elastase that enhances insulin signaling and might have a physiologic role in cellular glucose metabolism.

Elastases form a subfamily of serine proteases that hydrolyze many proteins in addition to elastin. Humans have six elastase genes which encode the structurally similar proteins elastase 1, 2, 2A, 2B, 3A, and 3B. Like most of the human elastases, elastase 2A is secreted from the pancreas as a zymogen. In other species, elastase 2A has been shown to preferentially cleave proteins after leucine, methionine, and phenylalanine residues.

Source: NCBI Gene 63036 — RefSeq curated summary.

At a glance

• Gene–disease (curated): abdominal obesity-metabolic syndrome 4 (Limited, GenCC)
• GWAS associations: 19
• Clinical variants (ClinVar): 58 total — 3 pathogenic, 2 likely-pathogenic
• Phenotypes (HPO): 11
• MANE Select transcript: NM_033440

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24609
Approved symbol	CELA2A
Name	chymotrypsin like elastase 2A
Location	1p36.21
Locus type	gene with protein product
Status	Approved
Aliases	ELA2A
Ensembl gene	ENSG00000142615
Ensembl biotype	protein_coding
OMIM	609443
Entrez	63036

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 2 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000359621, ENST00000459653, ENST00000497590, ENST00000967096

RefSeq mRNA: 1 — MANE Select: NM_033440 NM_033440

CCDS: CCDS157

Canonical transcript exons

ENST00000359621 — 8 exons

Exon	Start	End
ENSE00001595685	15463386	15463522
ENSE00001637775	15465999	15466144
ENSE00001693671	15456732	15456793
ENSE00001885503	15471990	15472091
ENSE00002685587	15462733	15462861
ENSE00003532875	15467386	15467538
ENSE00003549273	15461561	15461658
ENSE00003612435	15457086	15457174

Expression profiles

Bgee: expression breadth ubiquitous, 128 present calls, max score 99.88.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 64.9891 / max 118457.4976, expressed in 20 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
864	64.5466	19
863	0.1524	1
866	0.1220	3
867	0.1183	1
865	0.0279	1
862	0.0220	1

Top tissues by expression

132 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
body of pancreas	UBERON:0001150	99.88	gold quality
pancreas	UBERON:0001264	98.51	gold quality
islet of Langerhans	UBERON:0000006	95.74	gold quality
duodenum	UBERON:0002114	84.84	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	81.20	gold quality
right adrenal gland	UBERON:0001233	76.17	gold quality
left adrenal gland	UBERON:0001234	75.86	gold quality
left adrenal gland cortex	UBERON:0035825	74.82	gold quality
right adrenal gland cortex	UBERON:0035827	74.59	gold quality
ectocervix	UBERON:0012249	73.83	gold quality
fundus of stomach	UBERON:0001160	73.65	gold quality
right coronary artery	UBERON:0001625	72.91	gold quality
placenta	UBERON:0001987	72.03	gold quality
adrenal gland	UBERON:0002369	70.68	gold quality
right hemisphere of cerebellum	UBERON:0014890	70.63	gold quality
left uterine tube	UBERON:0001303	70.01	gold quality
right lobe of liver	UBERON:0001114	70.00	gold quality
body of stomach	UBERON:0001161	69.94	gold quality
endocervix	UBERON:0000458	69.38	gold quality
cerebellar hemisphere	UBERON:0002245	69.25	gold quality
cerebellum	UBERON:0002037	69.05	gold quality
cerebellar cortex	UBERON:0002129	68.95	gold quality
descending thoracic aorta	UBERON:0002345	67.01	gold quality
uterine cervix	UBERON:0000002	66.15	gold quality
stomach	UBERON:0000945	65.96	gold quality
lower esophagus mucosa	UBERON:0035834	65.82	gold quality
right ovary	UBERON:0002118	65.77	gold quality
right uterine tube	UBERON:0001302	65.74	gold quality
metanephros cortex	UBERON:0010533	65.57	gold quality
left ovary	UBERON:0002119	65.38	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-GEOD-81547	yes	9377.34
E-MTAB-5061	yes	19.36
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CREM, ERF, LEF1, RUNX1, USF1

Literature-anchored findings (GeneRIF, showing 4)

• analysis of regulation of hELA2 gene expression suggests transcriptional effects of AML1-ETO are more complex than simple DNA binding and repression via recruitment of corepressors (PMID:16247445)
• Complex Formation of Human Proelastases with Procarboxypeptidases A1 and A2. (PMID:27358403)
• CELA2A mutations resulting in high serum level is associated with early-onset atherosclerosis and metabolic syndrome. (PMID:31358993)
• Epithelial production of elastase is increased in inflammatory bowel disease and causes mucosal inflammation. (PMID:33674762)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	ela2	ENSDARG00000056744
danio_rerio	ela2l	ENSDARG00000056765
mus_musculus	Cela2a	ENSMUSG00000058579
rattus_norvegicus	Cela2a	ENSRNOG00000013628

Paralogs (6): CELA1 (ENSG00000139610), CELA3A (ENSG00000142789), PRTN3 (ENSG00000196415), ELANE (ENSG00000197561), CELA2B (ENSG00000215704), CELA3B (ENSG00000219073)

Protein

Protein identifiers

Chymotrypsin-like elastase family member 2A — P08217 (reviewed: P08217)

Alternative names: Elastase-2A

All UniProt accessions (1): P08217

UniProt curated annotations — full annotation on UniProt →

Function. Elastase that enhances insulin signaling and might have a physiologic role in cellular glucose metabolism. Circulates in plasma and reduces platelet hyperactivation, triggers both insulin secretion and degradation, and increases insulin sensitivity.

Subunit / interactions. Interacts with CPA1. Interacts with SERPINA1.

Subcellular location. Secreted.

Tissue specificity. Expressed in pancreas. Not detected in keratinocytes. Detected in exocrine secretions of the pancreas (at protein level). Also expressed in a small fraction of cells in pancreatic islets, adrenal cortex, intestinal glands and colonic lymphoid follicles (at protein level). Detected in plasma.

Disease relevance. Abdominal obesity-metabolic syndrome 4 (AOMS4) [MIM:618620] A form of abdominal obesity-metabolic syndrome, a disorder characterized by abdominal obesity, high triglycerides, low levels of high density lipoprotein cholesterol, high blood pressure, and elevated fasting glucose levels. AOMS4 is an autosomal dominant disease. Patients manifest obesity, hypertension, early-onset coronary artery disease and type 2 diabetes. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the peptidase S1 family. Elastase subfamily.

RefSeq proteins (1): NP_254275* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001254	Trypsin_dom	Domain
IPR001314	Peptidase_S1A	Family
IPR009003	Peptidase_S1_PA	Homologous_superfamily
IPR018114	TRYPSIN_HIS	Active_site
IPR033116	TRYPSIN_SER	Active_site
IPR043504
IPR050850	Peptidase_S1_Elastase_sf	Family

Pfam: PF00089

UniProt features (16 total): disulfide bond 4, sequence variant 4, active site 3, signal peptide 1, propeptide 1, sequence conflict 1, chain 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P08217-F1	93.66	0.91

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 73 (charge relay system); 121 (charge relay system); 216 (charge relay system)

Disulfide bonds (4): 212–243, 58–74, 155–222, 186–202

Function

Pathways and Gene Ontology

Reactome pathways

5 pathways

ID	Pathway
R-HSA-6809371	Formation of the cornified envelope
R-HSA-9925561	Developmental Lineage of Pancreatic Acinar Cells
R-HSA-1266738	Developmental Biology
R-HSA-6805567	Keratinization
R-HSA-9734767	Developmental Cell Lineages

MSigDB gene sets: 159 (showing top): GOBP_REGULATION_OF_CELL_ACTIVATION, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GRUETZMANN_PANCREATIC_CANCER_DN, GOBP_PLATELET_ACTIVATION, GOBP_INSULIN_SECRETION, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_REGULATION_OF_HORMONE_LEVELS, GOBP_HORMONE_TRANSPORT, GOBP_CELL_CELL_SIGNALING, GOBP_WOUND_HEALING, GOBP_CELL_CELL_ADHESION, GOBP_REGULATION_OF_PROTEIN_SECRETION, GOBP_REGULATION_OF_PLATELET_AGGREGATION, GOBP_RESPONSE_TO_INSULIN, MODULE_109

GO Biological Process (5): proteolysis (GO:0006508), response to insulin (GO:0032868), regulation of insulin secretion (GO:0050796), regulation of platelet aggregation (GO:0090330), insulin catabolic process (GO:1901143)

GO Molecular Function (7): endopeptidase activity (GO:0004175), serine-type endopeptidase activity (GO:0004252), serine hydrolase activity (GO:0017171), protein binding (GO:0005515), peptidase activity (GO:0008233), serine-type peptidase activity (GO:0008236), hydrolase activity (GO:0016787)

GO Cellular Component (4): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), cytosol (GO:0005829), keratohyalin granule (GO:0036457)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Developmental Biology	2
Keratinization	1
Developmental Cell Lineages of the Exocrine Pancreas	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
peptidase activity	2
hydrolase activity	2
cytoplasm	2
protein metabolic process	1
response to peptide hormone	1
insulin secretion	1
regulation of protein secretion	1
regulation of peptide hormone secretion	1
regulation of platelet activation	1
regulation of homotypic cell-cell adhesion	1
platelet aggregation	1
protein catabolic process	1
insulin metabolic process	1
endopeptidase activity	1
serine-type peptidase activity	1
binding	1
catalytic activity, acting on a protein	1
serine hydrolase activity	1
catalytic activity	1

Protein interactions and networks

STRING

729 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CELA2A	CPA1	P15085	766
CELA2A	CPA2	P48052	638
CELA2A	ELN	P15502	634
CELA2A	CPB1	P15086	591
CELA2A	PNLIPRP1	P54315	541
CELA2A	PNLIP	P16233	481
CELA2A	CEL	P19835	432
CELA2A	A2M	P01023	418
CELA2A	SYCN	Q0VAF6	413
CELA2A	CLPS	P04118	411
CELA2A	CUZD1	Q86UP6	382
CELA2A	AMY2A	P04746	372
CELA2A	RBPJL	Q9UBG7	366
CELA2A	AMY2B	P19961	365
CELA2A	PGA4	P00790	328

IntAct

5 interactions, top by confidence:

A	B	Type	Score
CELA2A	HGS	psi-mi:“MI:0914”(association)	0.350
MAS1	CELA2A	psi-mi:“MI:0914”(association)	0.350
CELA2A	CELA2B	psi-mi:“MI:0914”(association)	0.350
CELA2A	SERPINA1	psi-mi:“MI:0914”(association)	0.350

BioGRID (15): PDCD6IP (Affinity Capture-MS), SKI (Affinity Capture-MS), HGS (Affinity Capture-MS), ARID3B (Affinity Capture-MS), SMAD4 (Affinity Capture-MS), YLPM1 (Affinity Capture-MS), STAM (Affinity Capture-MS), ARID3A (Affinity Capture-MS), FLAD1 (Affinity Capture-MS), SARM1 (Affinity Capture-MS), CYLD (Affinity Capture-MS), ATG9A (Affinity Capture-MS), CELA2B (Affinity Capture-MS), CELA2A (Affinity Capture-MS), KCTD10 (Affinity Capture-MS)

ESM2 similar proteins: A0A126GUP6, A0A1S4H5M5, A0A6J1W8N1, B5U2W0, F5HKX0, O19023, O46644, O97366, P00772, P00773, P00774, P05208, P05805, P06871, P06872, P07477, P07478, P08217, P08218, P08419, P08861, P09093, P13582, P16049, P21902, P47796, P55091, P80009, P80010, Q29461, Q2VG86, Q3SYP2, Q49QW1, Q5R1M5, Q7M3E1, Q7M4I3, Q7PEV7, Q7QBP4, Q867B0, Q8I6K0

Diamond homologs: A0A182C2Z2, B8V7S0, O08762, O60235, P00747, P00760, P00762, P00765, P00766, P00767, P00774, P03951, P03952, P04070, P04813, P05981, P06867, P06871, P06872, P07146, P07338, P07477, P08217, P08426, P08519, P12545, P14272, P15944, P17538, P19799, P20231, P20918, P26262, P27435, P29786, P35033, P40313, P47796, P50342, P56677

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

58 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	2
Uncertain significance	39
Likely benign	5
Benign	0

Top pathogenic / likely-pathogenic (5)

Variant ID	HGVS	Classification
633592	NM_033440.3(CELA2A):c.361G>A (p.Asp121Asn)	Pathogenic
633594	NM_033440.3(CELA2A):c.639+1G>C	Pathogenic
633595	NM_033440.3(CELA2A):c.209C>T (p.Thr70Met)	Pathogenic
3385400	NM_033440.3(CELA2A):c.572G>A (p.Trp191Ter)	Likely pathogenic
633593	NM_033440.3(CELA2A):c.253C>A (p.Leu85Met)	Likely pathogenic

SpliceAI

1266 predictions. Top by Δscore:

Variant	Effect	Δscore
1:15456790:GGAG:G	donor_gain	1.0000
1:15456791:GAG:G	donor_gain	1.0000
1:15456791:GAGG:G	donor_gain	1.0000
1:15456792:AGG:A	donor_loss	1.0000
1:15456794:G:GG	donor_gain	1.0000
1:15457084:A:AG	acceptor_gain	1.0000
1:15457085:G:GG	acceptor_gain	1.0000
1:15461556:CCCA:C	acceptor_loss	1.0000
1:15461557:CCA:C	acceptor_loss	1.0000
1:15461558:CAG:C	acceptor_loss	1.0000
1:15461559:A:AC	acceptor_loss	1.0000
1:15462860:GG:G	donor_gain	1.0000
1:15462861:GG:G	donor_gain	1.0000
1:15463518:GCAGA:G	donor_gain	1.0000
1:15463521:GA:G	donor_gain	1.0000
1:15463523:G:GG	donor_gain	1.0000
1:15465997:A:AG	acceptor_gain	1.0000
1:15465998:G:GC	acceptor_gain	1.0000
1:15465998:GC:G	acceptor_gain	1.0000
1:15465998:GCC:G	acceptor_gain	1.0000
1:15465998:GCCA:G	acceptor_gain	1.0000
1:15467538:GGTAA:G	donor_loss	1.0000
1:15467539:GTAA:G	donor_loss	1.0000
1:15467540:T:G	donor_loss	1.0000
1:15456789:TGGAG:T	donor_gain	0.9900
1:15456790:GGAGG:G	donor_gain	0.9900
1:15456792:AG:A	donor_gain	0.9900
1:15456793:GG:G	donor_gain	0.9900
1:15457084:AG:A	acceptor_loss	0.9900
1:15457085:GC:G	acceptor_gain	0.9900

AlphaMissense

1740 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:15463509:G:C	W160C	0.999
1:15463509:G:T	W160C	0.999
1:15463391:A:C	D121A	0.997
1:15463396:G:C	A123P	0.997
1:15466109:T:A	C202S	0.997
1:15466110:G:C	C202S	0.997
1:15467433:G:C	W229C	0.997
1:15467433:G:T	W229C	0.997
1:15467455:T:C	F237L	0.997
1:15467457:C:A	F237L	0.997
1:15467457:C:G	F237L	0.997
1:15467529:G:C	W261C	0.997
1:15467529:G:T	W261C	0.997
1:15457169:T:A	W42R	0.996
1:15457169:T:C	W42R	0.996
1:15457171:G:C	W42C	0.996
1:15457171:G:T	W42C	0.996
1:15461653:C:G	C74W	0.996
1:15463391:A:T	D121V	0.996
1:15463494:C:G	C155W	0.996
1:15463507:T:A	W160R	0.996
1:15463507:T:C	W160R	0.996
1:15466061:T:A	C186S	0.996
1:15466062:G:A	C186Y	0.996
1:15466062:G:C	C186S	0.996
1:15466063:C:G	C186W	0.996
1:15466110:G:A	C202Y	0.996
1:15466111:T:G	C202W	0.996
1:15466140:G:A	C212Y	0.996
1:15467390:A:T	D215V	0.996

dbSNP variants (sampled 300 via entrez): RS1000449065 (1:15464015 G>A,T), RS1000635416 (1:15469474 A>C,G), RS1001680998 (1:15464809 G>A,C,T), RS1001717537 (1:15459576 A>G), RS1001983883 (1:15464646 A>C), RS1002146005 (1:15469839 C>A,T), RS1002232011 (1:15459788 T>C), RS1002246596 (1:15469997 G>C), RS1002498206 (1:15455415 G>A), RS1002666141 (1:15466090 C>A,T), RS1002817524 (1:15461174 C>T), RS1002970657 (1:15465822 G>A,C), RS1003538274 (1:15470993 A>G), RS1003614765 (1:15456658 T>C), RS1003676290 (1:15467205 A>G)

Disease associations

OMIM: gene MIM:609443 | disease phenotypes: MIM:618620

GenCC curated gene-disease

Disease	Classification	Inheritance
abdominal obesity-metabolic syndrome 4	Limited	Autosomal dominant

Mondo (4): abdominal obesity-metabolic syndrome 4 (MONDO:0032837), coronary artery disorder (MONDO:0005010), hypertensive disorder (MONDO:0005044), hypertriglyceridemia (MONDO:0005347)

Orphanet (0):

HPO phenotypes

11 total (11 of 11 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000822	Hypertension
HP:0001513	Obesity
HP:0001658	Myocardial infarction
HP:0001677	Coronary artery atherosclerosis
HP:0002155	Hypertriglyceridemia
HP:0003141	Increased LDL cholesterol concentration
HP:0003233	Decreased HDL cholesterol concentration
HP:0004943	Accelerated atherosclerosis
HP:0005978	Type II diabetes mellitus
HP:0040217	Elevated hemoglobin A1c

GWAS associations

19 associations (top):

Study	Trait	p-value
GCST000824_19	Erectile dysfunction and prostate cancer treatment	5.000000e-06
GCST004279_19	Systolic blood pressure	1.000000e-12
GCST004776_30	Systolic blood pressure	3.000000e-13
GCST004776_80	Systolic blood pressure	4.000000e-07
GCST004860_120	Alcoholic chronic pancreatitis	6.000000e-06
GCST004860_132	Alcoholic chronic pancreatitis	2.000000e-10
GCST004860_133	Alcoholic chronic pancreatitis	8.000000e-09
GCST004860_18	Alcoholic chronic pancreatitis	1.000000e-07
GCST004860_43	Alcoholic chronic pancreatitis	3.000000e-22
GCST004860_47	Alcoholic chronic pancreatitis	3.000000e-06
GCST004860_67	Alcoholic chronic pancreatitis	8.000000e-10
GCST004860_68	Alcoholic chronic pancreatitis	2.000000e-07
GCST004860_69	Alcoholic chronic pancreatitis	6.000000e-07
GCST004860_81	Alcoholic chronic pancreatitis	1.000000e-16
GCST004860_94	Alcoholic chronic pancreatitis	1.000000e-11
GCST006585_875	Blood protein levels	4.000000e-06
GCST007096_247	Pulse pressure	1.000000e-09
GCST007099_98	Systolic blood pressure	2.000000e-07
GCST007267_170	Systolic blood pressure	1.000000e-08

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0006335	systolic blood pressure
EFO:0005763	pulse pressure measurement

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D003324	Coronary Artery Disease	C14.280.647.250.260; C14.907.137.126.339; C14.907.585.250.260
D006973	Hypertension	C14.907.489
D015228	Hypertriglyceridemia	C18.452.584.500.500.851

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — S1: Chymotrypsin

CTD chemical–gene interactions

9 total (human), top 9 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
benzo(e)pyrene	increases methylation	1
Resveratrol	affects cotreatment, decreases expression	1
Arsenic Trioxide	increases expression	1
Arsenic	affects methylation	1
Doxorubicin	decreases expression	1
Methapyrilene	increases methylation	1
Phenytoin	decreases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Aflatoxin B1	increases methylation	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00025766	PHASE4	COMPLETED	Angioplasty and Heart Stents to Treat Individuals With an Occluded Artery Following a Heart Attack
NCT00079638	PHASE4	COMPLETED	Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL
NCT00110448	PHASE4	COMPLETED	Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial
NCT00111566	PHASE4	COMPLETED	BRIEF-PCI: Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention
NCT00129038	PHASE4	COMPLETED	Modified-release Dipyridamole/Aspirin (200mg/25mg bd) Versus Aspirin (75mg) in Aspirin-resistant Patients
NCT00133003	PHASE4	COMPLETED	Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2)
NCT00133237	PHASE4	COMPLETED	Drug-eluting-stents for Unprotected Left Main Stem Disease (ISAR-LEFT-MAIN)
NCT00133692	PHASE4	COMPLETED	INVEST: INternational VErapamil SR Trandolapril STudy
NCT00139386	PHASE4	COMPLETED	Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial
NCT00140465	PHASE4	COMPLETED	75 or 150 mg Clopidogrel Maintenance Doses Following PCI (ISAR-CHOICE-2)
NCT00140530	PHASE4	COMPLETED	Nonpolymer- and Polymer-Based Drug-Eluting Stents for Restenosis (ISAR-TEST-1)
NCT00146575	PHASE4	COMPLETED	Sirolimus- and Paclitaxel-Eluting Stents for Small Vessels (ISAR-SMART-3)
NCT00152308	PHASE4	TERMINATED	Non-Polymer-Based, Rapamycin-Eluting Stents to Prevent Restenosis
NCT00155350	PHASE4	UNKNOWN	Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients
NCT00162370	PHASE4	COMPLETED	A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronary Disease
NCT00163202	PHASE4	COMPLETED	Comparative Atorvastatin Pleiotropic Effects
NCT00169819	PHASE4	COMPLETED	EArly Discharge After Transradial Stenting of CoronarY Arteries: The EASY Study
NCT00171275	PHASE4	COMPLETED	Fluvastatin in the Therapy of Acute Coronary Syndrome
NCT00175240	PHASE4	COMPLETED	Enhancing the Secondary Prevention of Coronary Artery Disease
NCT00180388	PHASE4	TERMINATED	VENEK: Healing in Different Vein Harvesting Methods During Aortocoronary Coronary Artery Bypass Graft Surgery (CABG)
NCT00180583	PHASE4	COMPLETED	Vision II: Evaluation of GALILEO Intravascular Radiotherapy System
NCT00189215	PHASE4	COMPLETED	Long-Term Cognitive Decline After Coronary Artery Bypass Grafting: is Off-Pump Surgery Beneficial?
NCT00200629	PHASE4	TERMINATED	Both Exercise and Adenosine Stress Testing
NCT00202904	PHASE4	COMPLETED	Effectiveness and Safety of Ezetimibe Added to Atorvastatin in Patients With High Cholesterol and Coronary Heart Disease (Study P03740)
NCT00209404	PHASE4	COMPLETED	Iodixanol in Multidetector-Row Computed Tomography-Coronary Angiography (MDCT-CA)
NCT00209430	PHASE4	COMPLETED	Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Coronary Angiography
NCT00220558	PHASE4	UNKNOWN	GISSOC II: Sirolimus Eluting Stent Versus Bare Metal Stent in Chronic Total Coronary Occlusions
NCT00222261	PHASE4	COMPLETED	Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.
NCT00229528	PHASE4	COMPLETED	Effect of Paroxetine on COAT-Platelet Production in Normal Volunteers and Patients With Cardiovascular Disease
NCT00232804	PHASE4	COMPLETED	The BRIDGE Registry: Safety and Efficacy Registry of Bx Cypher Stent
NCT00232856	PHASE4	COMPLETED	A Study of the Cypher SES to Treat Restenotic Native Coronary Artery Lesions.
NCT00235066	PHASE4	COMPLETED	The CYPHER™ Stent Study in Patients With Small de Novo Coronary Artery Lesions.
NCT00235092	PHASE4	COMPLETED	The REALITY Study - Head-to-Head Comparison Between Cypher and Taxus
NCT00235950	PHASE4	COMPLETED	Assessment of the Lipid Lowering Effect of Rosuvastatin Compared to Atorvastatin in Subjects With Coronary Heart Disease
NCT00238004	PHASE4	UNKNOWN	The Low HDL On Six Weeks Statin Therapy (LOW) Study
NCT00241904	PHASE4	COMPLETED	Reducing Total Cardiovascular Risk in an Urban Community
NCT00242944	PHASE4	COMPLETED	Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-ACS)
NCT00243477	PHASE4	COMPLETED	MOTIV Study- Effect of Antidepressive Treatment by Escitalopram in Patients Undergoing Coronary Artery Bypass Grafting
NCT00244530	PHASE4	COMPLETED	Prophylactic Effect of Nifedipine on Further Decline in Renal Function in Patients Undergoing Open-Heart Surgery
NCT00245401	PHASE4	COMPLETED	CYPHERTM Stent Post-Marketing Surveillance Registry (US-PMS)